Recardio

Regenerative Cardiac

  • About Us
    • Profile
    • Management
    • Boards
    • Awards
  • Science
    • Background
    • Rationale
    • Therapy
  • Clinical
    • Phase 1
    • Phase 2B AMI
    • Phase 2B CHF
  • News Center

Jan 13 2020

Recardio at J.P. Morgan Conference 2020

San Francisco, January 13, 2020 – Recardio Inc., a clinical-stage life science company focusing on therapies for cardiovascular diseases, was participating in the 38th Annual J.P. Morgan Healthcare Conference  in San Francisco.

Read More

Written by Recardio · Categorized: Uncategorized

Dec 13 2019

Closing of Series B Financing Round

San Francisco, December 13th, 2019 – Recardio Inc., a clinical stage life science company developing regenerative therapies for cardiovascular diseases,announced the closing of its Series B financing round. 

Read More

Written by Recardio · Categorized: Uncategorized

Nov 06 2019

Recardio’s Digital Platform CardioCare Rolled Out in Europe

San Francisco, November 6th, 2019 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its it has rolled out its digital platform CardioCare throughout Europe to support its future clinical development programs in cardiovascular.

Read More

Written by Recardio · Categorized: Uncategorized

Oct 15 2019

Recardio at BIO Europe 2019

San Francisco, October 15, 2019 – Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, announced that it was presenting at the BIO Europe in Hamburg.

Read More

Written by Recardio · Categorized: Uncategorized

Sep 09 2019

Recardio’s Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin Now Enrolling and Recruiting in All Global Centers

San Francisco, September 9th, 2019 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction is now enrolling and recruiting in all multiple European and US centers.

Read More

Written by Recardio · Categorized: Uncategorized

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 6
  • Next Page »
  • Contact us
  • Imprint
  • Data Privacy

© Recardio inc. 2021 · All Rights Reserved

Copyright © 2021 · Recardio on Genesis Framework · WordPress · Log in